Featured Research

from universities, journals, and other organizations

Budesonide Provides Lasting Relief For Crohn's Disease Patients

Date:
September 13, 2005
Source:
Blackwell Publishing Ltd.
Summary:
In a study published in The American Journal of Gastroenterology, researchers found that budesonide capsules are an effective treatment to prolong and maintain the period of remission of Crohn's disease. Previous studies have demonstrated that budesonide is effective for inducing remission of Crohn's disease.

In a study published in The American Journal of Gastroenterology,researchers found that budesonide capsules are an effective treatmentto prolong and maintain the period of remission of Crohn's Disease.Previous studies have demonstrated that budesonide is effective forinducing remission of Crohn's disease.

Related Articles


Four double-blind, placebo-controlled trials were conducted withidentical protocols in which patients with Crohn's Disease, andmedically induced remission, received a treatment of oral budesonidefor 12 months. Results showed that budesonide taken at 6 mg/day iseffective for prolonging time to relapse and for significantly reducingrates of relapse.

"Long-term treatment with budesonide is well-tolerated and thefrequency and types of adverse events are similar to placebo," stateslead researcher,William J. Sandborn, MD. "Safety of a long-termmedication is obviously important, but how well a patient toleratestheir medication is also important and can affect patient adherence totherapy."

Crohn's disease is a long-term disease that results from inflammationof the digestive tract. It is a debilitating sickness, even forpatients who are classified as having mild to moderate disease.Currently, there are no treatment options available that preventsrecurrence of symptoms.

"As stated, this disease is recurring in nature, so extending the timea patient can be symptom-free or with diminished symptoms is animportant feature of treatment. Budesonide capsules are a treatmentoption for Crohn's disease that has been shown in studies not only tobe very effective in relieving symptoms, but also in extending the timebefore patients experience a recurrence."

###

This study is published in The American Journal of Gastroenterology.

Dr.William J. Sandborn is a board certified gastroenterologist withspecific expertise in inflammatory bowel disease. He has publishedextensively in this field, both nationally and internationally.

About The American Journal of Gastroenterology
The American Journal of Gastroenterology, the official publication ofthe American College of Gastroenterology, is THE clinical journal forall practicing gastroenterologists, hepatologists and GI endoscopists.With an impact factor of 4.716, it is the authoritative clinical sourcein the field of gastroenterology. With a broad-based, rigorous,interdisciplinary approach, the journal presents the latest importantinformation in the field of gastroenterology including originalmanuscripts, meta-analyses and reviews, health economic papers, debatesand consensus statements of clinical relevance in gastroenterology. Thereports will highlight new observations and original research, resultswith innovative treatments and all other topics relevant to clinicalgastroenterology. Case reports highlighting disease mechanisms orparticularly important clinical observations and letters on articlespublished in the Journal are included.

About Blackwell Publishing
Blackwell Publishing is theworld's leading society publisher, partnering with more than 600academic and professional societies. Blackwell publishes over 750journals annually and, to date has published close to 6,000 text andreference books, across a wide range of academic, medical, andprofessional subjects.


Story Source:

The above story is based on materials provided by Blackwell Publishing Ltd.. Note: Materials may be edited for content and length.


Cite This Page:

Blackwell Publishing Ltd.. "Budesonide Provides Lasting Relief For Crohn's Disease Patients." ScienceDaily. ScienceDaily, 13 September 2005. <www.sciencedaily.com/releases/2005/09/050913123928.htm>.
Blackwell Publishing Ltd.. (2005, September 13). Budesonide Provides Lasting Relief For Crohn's Disease Patients. ScienceDaily. Retrieved April 20, 2015 from www.sciencedaily.com/releases/2005/09/050913123928.htm
Blackwell Publishing Ltd.. "Budesonide Provides Lasting Relief For Crohn's Disease Patients." ScienceDaily. www.sciencedaily.com/releases/2005/09/050913123928.htm (accessed April 20, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, April 20, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Humanoid Robot Can Recognise and Interact With People

Humanoid Robot Can Recognise and Interact With People

Reuters - Innovations Video Online (Apr. 20, 2015) An ultra-realistic humanoid robot called &apos;Han&apos; recognises and interprets people&apos;s facial expressions and can even hold simple conversations. Developers Hanson Robotics hope androids like Han could have uses in hospitality and health care industries where face-to-face communication is vital. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Labour Party Warns Britain's Health Service 'on Life Support'

Labour Party Warns Britain's Health Service 'on Life Support'

AFP (Apr. 20, 2015) Britain&apos;s opposition Labour Party Monday claimed the National Health Service (NHS) was &apos;on life support&apos; as it turned its attention to the state-run service, which is a key issue for the UK&apos;s May 7 general election. Video provided by AFP
Powered by NewsLook.com
Sierra Leone Students Back to School After Long Ebola Closure

Sierra Leone Students Back to School After Long Ebola Closure

Reuters - News Video Online (Apr. 20, 2015) After an eight-month break, children in Sierra Leone return to school for the first time since the beginning of the Ebola outbreak. Nathan Frandino reports. Video provided by Reuters
Powered by NewsLook.com
Teen E-Cigarette Use Triples, Government Debates Regulations

Teen E-Cigarette Use Triples, Government Debates Regulations

Newsy (Apr. 19, 2015) The Centers for Disease Control and Prevention says in 2014, 13.4 percent of high school students reported smoking an e-cigarette within 30 days. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins